37.04
price up icon1.79%   0.65
pre-market  プレマーケット:  35.63   -1.41   -3.81%
loading

Exelixis Inc (EXEL) 最新ニュース

pulisher
Apr 02, 2025

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey

Apr 02, 2025
pulisher
Apr 02, 2025

Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Exelixis Launches Special Equity Award Program - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 29, 2025

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch

Mar 26, 2025
pulisher
Mar 26, 2025

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe

Mar 26, 2025
pulisher
Mar 26, 2025

(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire

Mar 26, 2025
pulisher
Mar 26, 2025

Proficio Capital Partners LLC Takes $706,000 Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace

Mar 25, 2025
pulisher
Mar 25, 2025

Looking Into Exelixis's Recent Short Interest - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st

Mar 25, 2025
pulisher
Mar 24, 2025

Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN

Mar 24, 2025
pulisher
Mar 21, 2025

Interesting EXEL Put And Call Options For November 21st - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily

Mar 20, 2025
pulisher
Mar 20, 2025

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

Exelixis Growth Continues with Big Money Boosts - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire

Mar 18, 2025
pulisher
Mar 18, 2025

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 15, 2025

15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 15, 2025
pulisher
Mar 13, 2025

What 25 Analyst Ratings Have To Say About Exelixis - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts (NASDAQ:EXEL) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 13, 2025

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? - Yahoo

Mar 13, 2025
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
大文字化:     |  ボリューム (24 時間):